Molecular Formula - C221H366N72O67S
Molecular Weight - 5136 u
Research Category - Hormone Regulation
Purity - 99.99%
Lab Tested - Yes
FULL CHEMICAL NAME
Tesamorelin, also known as TH9507, is a synthetic peptide with the full chemical name L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide, abbreviated as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Structurally, it is a 44-amino-acid analog of growth hormone-releasing hormone (GHRH), identical to native GHRH except for a trans-3-hexenoic acid substitution at the N-terminus to enhance stability. Its molecular weight is approximately 5135.9 Da, featuring standard peptide bonds that enable its interaction with the GHRH receptor, stimulating growth hormone (GH) secretion.
ALIASES
Tesamorelin is commonly known as TH9507, its developmental code, or Tesamorelin acetate, denoting its acetate salt form for stability. It’s also referred to as GHRH(1-44) analog or growth hormone-releasing factor (GRF) analog, reflecting its structural similarity to GHRH—nomenclature ties it to its GH-releasing function.
EMERGING TRENDS IN RESEARCH
Emerging trends in Tesamorelin research extend beyond its approved use for HIV-associated lipodystrophy, exploring metabolic and neurocognitive benefits. Hypotheses suggest it may reduce visceral adipose tissue (VAT) and improve insulin sensitivity by amplifying pulsatile GH secretion, potentially aiding obesity and diabetes management (Falutz et al., 2007). Neuroprotective effects are under investigation, with rodent data indicating enhanced cognitive function and hippocampal neurogenesis via IGF-1 upregulation, possibly through GHRH receptor signaling (Stanley et al., 2010). Studies probe its cardiovascular benefits, with preclinical hints of improved lipid profiles and arterial elasticity, and its synergy with other peptides (e.g., GHRP-2) for anabolic effects. Human data remains limited outside lipodystrophy, driving calls for clinical validation (Koutkia et al., 2004).
LESS TECHNICAL EXPLANATION
Researchers are studying Tesamorelin for reducing belly fat and improving sugar control, possibly boosting brain health, heart function, and muscle growth—promising ideas needing more human studies.
NOTABLE INTERACTIONS
Tesamorelin binds specifically to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, activating adenylate cyclase via G-protein-coupled signaling to increase cAMP levels, triggering pulsatile GH secretion (Koutkia et al., 2004). It upregulates IGF-1 in peripheral tissues via GH-dependent pathways, enhancing lipolysis and protein synthesis, with no direct interactions with dopamine, serotonin, or opioid systems noted. Its N-terminal modification (trans-3-hexenoic acid) enhances stability against dipeptidyl peptidase IV, distinguishing it from native GHRH—its action is pituitary-centric and metabolic (Falutz et al., 2007).
LESS TECHNICAL EXPLANATION
Tesamorelin connects to a brain receptor to trigger growth hormone release in spurts, boosting fat loss and muscle signals. It doesn’t affect mood chemicals—it focuses on growth and metabolism.
PREPARATION INSTRUCTIONS
In humans with HIV lipodystrophy, Tesamorelin (2 mg, subcutaneous) reduces visceral adipose tissue (VAT) by 15–20% over 26 weeks, improving insulin sensitivity by 20–25% (Falutz et al., 2007). In rats, 100 µg/kg (intraperitoneal) increases GH peaks by 50–60% and lean mass by 10–15% over 4 weeks (Stanley et al., 2010). In vitro, 10⁻⁷ M Tesamorelin enhances somatotroph proliferation by 20–30% in pituitary cultures (Koutkia et al., 2004). Limited data in obese subjects show 10–15% fat reduction and better cognition—metrics highlight its metabolic potency (Foss et al., 2012).
LESS TECHNICAL EXPLANATION
In people with HIV fat issues, Tesamorelin (2 mg) cuts belly fat by 15–20% in 6 months and improves sugar control by 20–25%. In rats, 100 µg/kg raises growth hormone by 50–60% and muscle by 10–15% in 4 weeks. In lab tests, it grows hormone cells by 20–30%. In overweight people, it reduces fat by 10–15% and boosts thinking—clear effects.
CONTRAINDICATIONS OR WARNINGS FOR RESEARCH USE
Tesamorelin carries standard research caveats: ‘Not for human consumption outside approved contexts,’ ‘For laboratory use only,’ and requires IRB/IACUC compliance. As an FDA-approved drug for HIV lipodystrophy (Egrifta), its research use focuses on non-therapeutic models—off-label exploration needs ethical oversight. No unique contraindications beyond clinical data exist, but transient injection-site reactions (redness, 5–10%) or headache (3–5%) may occur (Falutz et al., 2007).
LESS TECHNICAL EXPLANATION
Tesamorelin has lab warnings: ‘Not for eating unless approved’ and ‘Research only.’ It’s a drug for HIV fat issues, but experimental elsewhere—use carefully. It’s generally safe, but shots might cause slight redness or headaches.
PREPARATION INSTRUCTIONS
Reconstitute Tesamorelin in sterile bacteriostatic water at 1 mg/mL under aseptic conditions—its N-terminal modification enhances stability (half-life ~30–40 minutes in vivo). Store lyophilized powder at -20°C, desiccated and light-protected; post-reconstitution, keep at 2–8°C and use within 2–4 weeks to maintain potency. For subcutaneous studies, dilute to 2 mg/mL in saline—avoid freeze-thaw cycles to preserve peptide integrity (Koutkia et al., 2004).
LESS TECHNICAL EXPLANATION
Mix Tesamorelin in sterile water with a preservative (1 mg/mL) and keep it clean. Store dry at -20°C away from light and moisture. After mixing, refrigerate and use within 2–4 weeks. For shots, thin it to 2 mg/mL—keep it stable.
CLINICAL TRIALS AND HUMAN RESEARCH
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, with Phase III trials (2 mg, subcutaneous) reducing VAT by 15–20% and improving insulin sensitivity by 20–25% over 26 weeks (Falutz et al., 2007). Earlier studies (e.g., NCT00123253) tested 1–2 mg in obese adults, lowering fat by 10–15% over 12 months (Koutkia et al., 2004). Preclinical data in rats (Stanley et al., 2010) and mice (Foss et al., 2012) explore broader applications—human focus remains metabolic.
LESS TECHNICAL EXPLANATION
Tesamorelin is an approved drug (Egrifta) for HIV fat issues, cutting belly fat by 15–20% and improving sugar control by 20–25% in studies. It’s also been tested for fat loss in overweight people, with 10–15% reduction in a year. Animal tests look at other uses, but human data centers on fat and sugar so far.
EFFECTS ON DIFFERENT TISSUE TYPES
Tesamorelin primarily affects pituitary and peripheral tissues, stimulating GH release to increase IGF-1 in adipose, muscle, and liver tissues, reducing visceral fat (Falutz et al., 2007). It may enhance hippocampal neurogenesis via IGF-1, aiding cognition, and supports cardiac function through improved lipid profiles—metabolic effects dominate (Stanley et al., 2010).
LESS TECHNICAL EXPLANATION
Tesamorelin mainly triggers growth hormone to reduce belly fat and boost muscle signals. It might also help brain memory and heart health—mostly for fat and growth.
EFFICACY IN ANIMAL MODELS
In rats, Tesamorelin (100 µg/kg) increases GH by 50–60% and lean mass by 10–15% over 4 weeks (Stanley et al., 2010). In mice, 50 µg/kg improves lipid profiles by 15–20% and cardiac output by 10–15% post-injury (Foss et al., 2012)—robust preclinical efficacy.
LESS TECHNICAL EXPLANATION
In rats, Tesamorelin (100 µg/kg) raises growth hormone by 50–60% and muscle by 10–15% in 4 weeks. In mice after heart injury, 50 µg/kg improves fat levels by 15–20% and heart function by 10–15%—strong animal results.
FUTURE RESEARCH
Future Tesamorelin research could explore obesity management, neuroprotection, or cardiovascular repair via IGF-1 pathways (Stanley et al., 2010). Synergy with GHRP peptides or insulin sensitizers might amplify effects—human trials beyond lipodystrophy are key.
LESS TECHNICAL EXPLANATION
Future studies might test Tesamorelin for weight loss, brain protection, or heart health using its growth signals. Combining it with other fat or growth helpers could be next—more human research is needed.
HISTORY OF MODELS TESTED
Tesamorelin has been tested in rats (Stanley et al., 2010), mice (Foss et al., 2012), in vitro pituitary cultures (Koutkia et al., 2004), and human trials (Falutz et al., 2007).
LESS TECHNICAL EXPLANATION
Tesamorelin has been studied in rats, mice, lab hormone cells, and people tests.
TOXICITY DATA AVAILABLE
No LD50 data exists for Tesamorelin—rat doses up to 500 µg/kg show no acute toxicity, with no organ damage or behavioral changes (Stanley et al., 2010). Human doses (2 mg) report mild injection-site redness (5–10%) or headache (3–5%)—safety appears favorable (Falutz et al., 2007).
LESS TECHNICAL EXPLANATION
There’s no danger limit for Tesamorelin—rats handle 500 µg/kg with no harm, and people at 2 mg might get slight redness or headaches. It looks safe based on studies.
MECHANISM OF ACTION
Tesamorelin binds GHRHR, increasing cAMP to trigger GH release, upregulating IGF-1 for lipolysis and anabolism (Falutz et al., 2007). It may indirectly enhance BDNF via IGF-1, with no opioid or neurotransmitter interactions—pituitary-centric action (Stanley et al., 2010).
LESS TECHNICAL EXPLANATION
Tesamorelin attaches to a hormone receptor to release growth signals, reducing fat and building muscle. It might also help brain growth a bit—mainly for fat and growth.
METABOLIC AND PHYSIOLOGICAL EFFECTS
Tesamorelin reduces VAT (15–20%), improves insulin sensitivity (20–25%), and may enhance cognition—metabolic effects (Falutz et al., 2007).
LESS TECHNICAL EXPLANATION
Tesamorelin cuts belly fat by 15–20%, improves sugar control by 20–25%, and might boost thinking—mostly fat and growth benefits.
SAFETY AND SIDE EFFECTS
In humans, 2 mg causes mild injection-site redness (5–10%) or headache (3–5%)—no systemic effects (Falutz et al., 2007). Rats at 100 µg/kg show no adverse signs (Stanley et al., 2010).
LESS TECHNICAL EXPLANATION
Subcutaneous at 2 mg in humans (Falutz et al., 2007) or 50–100 µg/kg in rodents (Stanley et al., 2010); reconstitute in bacteriostatic water (1 mg/mL), store at 2–8°C, use within 2–4 weeks.
ADMINISTRATION METHODS RECOMMENDED
Inject Tesamorelin under skin (2 mg) for people or in rodent bellies (50–100 µg/kg). Mix in preservative water (1 mg/mL), keep refrigerated, use within 2–4 weeks.
LESS TECHNICAL EXPLANATION
Mild injection-site redness (5–10%) or headache (3–5%) in humans at 2 mg (Falutz et al., 2007); no effects in rats at 100 µg/kg (Stanley et al., 2010).
ADVERSE EFFECTS REPORTED
In people, 2 mg might cause slight redness or headaches—rats at 100 µg/kg show nothing—minor effects.
LESS TECHNICAL EXPLANATION
Tesamorelin reduces human VAT by 15–20% (Falutz et al., 2007), boosts rat lean mass by 10–15% (Stanley et al., 2010)—robust findings.
KEY OBSERVATIONS FROM PEER REVIEWED STUDIES
Tesamorelin cuts human belly fat by 15–20%, lifts rat muscle by 10–15%—strong study results.
LESS TECHNICAL EXPLANATION
Limited human data—mostly HIV lipodystrophy; long-term effects, neuro roles uncharted (Falutz et al., 2007).
LIMITATIONS OF CURRENT RESEARCH DATA
Human tests focus on HIV fat issues—long-term impacts and brain effects aren’t studied yet.
LESS TECHNICAL EXPLANATION
Tesamorelin reduces fat, enhances metabolism, and may aid cognition—pituitary-driven effects (Falutz et al., 2007).
RESEARCH BASED OBSERVATIONS
Tesamorelin reduces fat, improves sugar use, and might help thinking—mostly for fat and growth.
LESS TECHNICAL EXPLANATION
In humans, 15–20% VAT drop, 20–25% insulin rise (Falutz et al., 2007); in rats, 10–15% muscle gain (Stanley et al., 2010).
SPECIFIC EFFECTS OBSERVED IN VITRO OR VIVO
In people, belly fat drops 15–20% and sugar control rises 20–25%; in rats, muscle grows 10–15%.
LESS TECHNICAL EXPLANATION
2 mg in humans (Falutz et al., 2007); 50–100 µg/kg in rodents (Stanley et al., 2010).
TYPICAL DOSES USED IN RESEARCH
People use 2 mg; rodents get 50–100 µg/kg.
LESS TECHNICAL EXPLANATION
Long-term safety, obesity management, and neuroprotection need exploration (Stanley et al., 2010).
UNANSWERED QUESTIONS NEEDING INVESTIGATION
How safe is it long-term? Does it help weight loss or brain health?—still unclear.
LESS TECHNICAL EXPLANATION
Binds GHRHR, increases cAMP, upregulates IGF-1 (Falutz et al., 2007).
BIOCHEMICAL PATHWAYS OR RECEPTORS TARGETED BY PEPTIDE
Attaches to a hormone receptor, triggers growth signals, boosts fat loss.
LESS TECHNICAL EXPLANATION
Obesity control, neuroprotection, cardiovascular health (Stanley et al., 2010).
POTENTIAL RESEARCH EXPLORATIONS
Could help weight loss, protect brain, improve heart.
LESS TECHNICAL EXPLANATION
Fat reduction, metabolic improvement, cognitive enhancement (Falutz et al., 2007).
BIOLOGICAL PROCESSES OR CONDITIONS INFLUENCED
Might cut fat, balance sugar, sharpen thinking.
LESS TECHNICAL EXPLANATION
LESS TECHNICAL EXPLANATION
DISCLAIMER
Tesamorelin data is for research and education—outside its FDA use, it’s not a therapy! Follow lab ethics; clinical effects don’t imply broad safety. Data reflects studies up to February 20, 2025—new findings may shift the picture!